TDXd for Brain Metastases: The Baseball Slugger

Exploring the significant findings from DESTINY-Breast12, Drs. Callahan and Bardia illustrate how T-DXd has become the preferred treatment for HER2-positive and HER2-low breast cancer patients with brain metastases, reshaping clinical practice standards.

Topics Covered:
• T-DXd’s effectiveness against brain metastases
• Clinical preference shift from traditional regimens
• Mechanism of T-DXd’s CNS activity